What is Xeris Biopharma Holdings, Inc.'s total revenue?

Xeris Biopharma Holdings, Inc. (XERS) reported total revenue of $83.13M in Q1 2026.

How has Xeris Biopharma Holdings, Inc.'s total revenue changed year-over-year?

Xeris Biopharma Holdings, Inc.'s total revenue increased by 38.3% year-over-year, from $60.12M to $83.13M.

What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total revenue?

Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s total revenue has grown at a 55.8% compound annual growth rate (CAGR), from $49.59M to $291.85M.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Xeris Biopharma Holdings, Inc. XERS Total Revenue

Total Revenue at other companies

Eli LillyLLY

$19.8B+55.5%

Corcept TherapeuticsCORT

$164.9M+4.9%

Eton Pharmaceuticals, Inc.ETON

$24.27M+40.4%

Ultragenyx PharmaceuticalRARE

$136M-2.2%

ANI PharmaceuticalsANIP

$237.46M+20.5%

Crinetics PharmaceuticalsCRNX

$10.73M+2,873%

Segments

By product

See full

Recorlev$49.77M+94.9%

Gvoke$20.8M-0.2%

Keveyis$11.89M+4.0%

Royalty, contract and other revenue$673K-71.0%

Other financials

Income statement

See full

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Balance sheet

See full

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Cash flow

See full

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Valuation

See full

Market cap$1.28B+18.3%

Enterprise value$1.42B+8.7%

P/E106.4×—

P/S4.1×-0.8×

Profitability

See full

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-209.8%—

Debt / equity19.9×—

Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s total revenue?: Xeris Biopharma Holdings, Inc. (XERS) reported total revenue of $83.13M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s total revenue changed year-over-year?: Xeris Biopharma Holdings, Inc.'s total revenue increased by 38.3% year-over-year, from $60.12M to $83.13M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total revenue?: Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s total revenue has grown at a 55.8% compound annual growth rate (CAGR), from $49.59M to $291.85M.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.